We performed a prospective, randomized, double-blind trial in 194 unselected patients to determine the safety and efficacy of low molecular weight heparin (Fragmin) compared with standard heparin as the initial treatment of acute venous thromboembolism. Ninety-eight patients received continuous intravenous heparin, and 96 patients received Fragmin for 5-10 days. Doses were adjusted to maintain anti-Xa levels between 0.3 and 0.6 unit/ml for patients with a high risk for a bleeding complication and between 0.4 and 0.9 unit/ml for patients with a low risk for bleeding. Treatment was stopped when a therapeutic level of anticoagulation (International Normalized Ratio >3.5) was reached with coumarins. Thirteen patients in the heparin group and 10 patients in the Fragmin group had a major bleeding complication. The incidence of major and minor bleeding complications combined decreased from 48.9% to 38.5% (95% confidence interval for the dilference, -3.5% to +24.2%), corresponding with a relative bleeding risk reduction of 21.2%. There were no significant differences in efficacy as defined by new high-probability defects on repeat ventilation-perfusion scintigraphy of the lung in 80 patients: six of 46 patients in the heparin group and 3 of 34 patients in the Fragmin group had new defects (95% confidence interval for the difference, -9.4% to + 17.8%). We conclude that low molecular weight heparin (Fragmin) given in adjusted, continuous, and intravenous doses is safe and effective as initial treatment of acute venous thromboembolism compared with heparin. There is a trend in risk reduction for bleeding in favor of low molecular weight heparin, a trend, however, that is smaller than expected compared with animal studies. (Circulation 1989;80:935-940) H eparin is used in relatively large doses in the management of thromboembolic disease with the aim of preventing extension and embolization of venous thrombi. The treatment, however, is associated with an appreciable risk of hemorrhage. This has prompted research to improve the benefit to risk ratio of the drug.
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Heparin acts as an anticoagulant by accelerating the complex formation between antithrombin III and various activated clotting factors, among which factor Xa and thrombin are the most important. Fractionation of the polydisperse heparin according to molecular size has led to the development of low molecular weight heparin preparations with an increased anti-Xa to antithrombin ratio.1 These low possess definite anticoagulant and antithrombotic effects but to cause less bleeding in animal models. [2] [3] [4] [5] [6] Clinical studies in humans have shown that low molecular weight heparins are effective in preventing postoperative venous thromboembolism.7-9 These studies, however, have not clarified whether or not these preparations also prevent extension and embolization of thrombi in patients with overt thrombosis. Furthermore, it still has to be established in humans whether or not low molecular weight heparins produce less bleeding for equivalent antithrombotic efficacy.
For these reasons, we conducted a clinical trial to assess the safety and efficacy of a low molecular weight heparin preparation, Fragmin, in comparison to standard heparin in the treatment of unselected patients with overt venous thromboembolism. The trial was especially designed to study the effect of low molecular weight heparin on the incidence of bleeding in humans.
Methods
The study was a prospective, randomized, doubleblind investigation comparing Fragmin (Kabi 2165) with standard heparin in the treatment of unselected patients with venous thromboembolism in the University Hospital Utrecht, starting January 1985.
The study protocol was approved by the ethical committee of the hospital. All patients with clinical symptoms of deep venous thrombosis of the leg, axillary vein thrombosis, or pulmonary embolism were eligible for the study. Exclusion criteria were allergy for heparin, pregnancy, and objection by the patient's physician to the heparin levels of the study.
Patients entering the study were asked for informed consent and were stratified according to bleeding risk. The high-risk group was defined as women over 60 years, men over 70 years, surgery within the preceding 10 days, renal insufficiency (creatinine level >45.2 mg/l [400 ,umol/l]), recent intracranial bleeding or stroke, active peptic disease, hypertension (diastolic pressure > 120 mm Hg or fundal changes > stage 2), recent cardiopulmonary resuscitation (<10 days), history of subarachnoidal bleeding, and history of bleeding diathesis and general disability (WHO score 4).10 The low-risk group contained all other patients. Allocation to one or the other treatment was randomized. Fragmin is the sodium salt of a low molecular weight heparin derivate (specific activity, 10,000 anti-Xa units/ml; calibrated against the first International Standard for low molecular weight heparin) and is prepared from pig mucosal heparin by partial degradation with nitrous acid and has a molecular weight between 4,000 and 6,000 daltons. Standard heparin is a porcine mucosal sodium heparin (specific activity, 20,000 units/ml; calibrated against the fourth International Heparin Standard by chromogenic assay). Both were supplied by KabiVitrum AB, Stockholm, Sweden. Both drugs were delivered in ampoules containing 1 ml of a clear, colorless fluid.
All patients received an intravenous bolus injection of 1 ml containing 2,500 anti-Xa units heparin or Fragmin and a continuous infusion (administered with a pump through an intravenous catheter in the forearm) of 1.5 ml of the drug dissolved in saline, corresponding to 30,000 units/24 hr heparin or 15,000 units anti-Xa/24 hr Fragmin. These doses were based on previous studies1" 12 and on a pilot study showing that similar anti-Xa levels were reached with half the amount of Fragmin.
Anti-Xa assays were performed 4 hours after the start of the treatment, 4 hours after any dose adjustment, and furthermore, daily at 9:00 AM and 4:00 PM. The dose was adjusted to give anti-Xa levels between 0.4 and 0.9 unit/ml in the low-risk group and between 0.3 and 0.6 unit/ml in the highrisk group. Anti-Xa activity was assayed from blood, collected in tubes containing sodium citrate, with the Coatest of KabiVitrum according to the antifac- with Sl"Krand 99mTc-loaded macroaggregates17 or in exceptional cases (massive pulmonary embolism with cyanosis) by pulmonary angiography. Treatment was stopped in patients in whom the provisional diagnosis was not confirmed. These patients and patients who could not continue the trial for at least 3 days for reasons not related to the trial therapy were categorized as "dropouts" and were replaced in the randomization procedure. They were not included in the final analysis.
Therapy with oral anticoagulants was started after confirmation of the diagnosis at the discretion of the patient's physician. Heparin and Fragmin treatment was continued for at least 5 days and stopped when a sufficient level of anticoagulation was reached with oral anticoagulants. This was assayed, after neutralization with protamine sulphate, in a prothrombin time assay using rabbit brain thromboplastin (Dade, Aguada, Puerto Rico) with an International Sensitivity Index (ISI) of 2.3.
Follow-up of the patients consisted of a daily physical examination by the investigator, and the following data were recorded: signs of bleeding or other side effects, blood pressure, respiration rate, pain, tenderness and circumference of the affected limb, and the number of blood transfusions given. Urinalysis for erythrocyte level, stool analysis for occult blood, platelet count determination, and hemoglobin level determination were performed daily. Liver function tests and creatinine level determination were performed before, on day 3 or 4, and at the end of treatment.
Whenever possible, a lung scan was performed before and after the treatment, irrespective of the initial diagnosis. A bilateral impedance plethysmography was performed before and immediately after stopping the infusion therapy in all patients. A rise in the absolute value of the venous function index of the diseased leg after treatment together with a decrease in the difference in the venous function index between the diseased and the healthy leg at the second investigation was considered as an improvement of the findings of the bilateral impedance plethysmography.
Primary endpoints were major and minor bleeding and recurrence. Major bleeding was defined as bleeding that leads to death, to interruption of treatment, to blood transfusion, or to a fall in hemoglobin level of more than 2.42 g% (1.5 mmol/ bosis was confirmed with bilateral impedance 1). Minor bleeding was defined as any overt bleeding that does not meet the criteria of a major bleeding. Recurrence was defined as one or more new segmental defects on the second perfusion scan (without infiltrative abnormalities on the chest radiograph) or death by pulmonary embolism found at autopsy or suspected on clinical grounds when autopsy was not allowed. Patients withdrawn from the study by their attending physician because of progressive thrombotic disease leading to surgical intervention or thrombolytic therapy were also recorded as recurrences.
Patients who did not continue treatment because of reasons related to trial therapy were categorized as "discontinuations." They were part of the final analysis.
The risk of bleeding complications in patients receiving therapeutic doses of heparin has been reported to range from 1% to 33%, and this great variation in bleeding incidence became a major problem in determining the sample size. We anticipated that in our population of patients with venous thromboembolism the frequency of bleeding complications during heparin therapy would be 15%. A reduction to 3% seemed a clinically important benefit, and this reduction was judged to be possible on the basis of animal studies. It was estimated that 104 patients in each treatment group were required to give 80% probability of detecting a statistically significant difference at the 5% level of confidence.18
Statistical Analysis
Differences between the two groups were tested for statistical significance by independent t tests (two tailed) and x2 tests as appropriate. Whenever the variables were not normally distributed, Wilcoxon's ranked sum test was used to analyze the data.
Results

Patients
During the trial period from 1 January 1985 to 1 July 1987, 219 patients were randomized for the trial. There were 24 dropouts: in 21 patients, the initial clinical diagnosis proved to be incorrect, and three patients could not continue the trial for 3 days for reasons not related to trial therapy. One of these patients was referred to a nursing home on day 2, one patient died on day 2 from a septic shock (autopsy findings), and one patient had a laparotomy on day 2 because of necrosis in an ovarian tumor. One patient was considered to be nonevaluatable; he was known for paroxysmal nocturnal hemoglobinuria and had severe hemolysis with hemoglobinuria. These patients were replaced and not included in the analysis.
Of the 194 treated patients, 115 had a primary diagnosis of deep venous thrombosis, 70 a primary diagnosis of pulmonary embolism, and nine had an axillary vein thrombosis. Ninety-eight patients received therapy with heparin, and 96 received Fragmin. The treatment groups did not differ signif- 19 17 World Health Organization score 4 13 14 Brain infarction 5 4 Bleeding diathesis 6 3 Cardiopulmonary resuscitation icantly in baseline characteristics (Tables 1 and 2) with the exception of a preponderance of women in the heparin group and the presence of four women in this same group who used estrogens.
Retrospectively, we found that from all patients with a diagnosis of venous thromboembolic disorder in our hospital in the study period, 89% (198 of 225 patients) participated in the study. Reasons for not entering or for exclusion were primary treatment with streptokinase (four patients), heparin therapy started before investigators were informed (10 patients), pregnancy (three patients), and objec- (Figure 2 ). tion of the attending physician against the anti-Xa levels of the protocol (10 patients).
Levels ofAnticoagulation
Treatment duration was similar for both groups: 5.9± 1.3 days (mean±SD) for heparin, and 6.3± 1.4 days for Fragmin. The anti-Xa levels in both groups were not different at any moment (Figure 1 ). These levels were reached with a mean dose of 31,000 Deaths and Discontinuations During our study, two patients, both treated with heparin, died while on therapy. One patient died of fatal liver bleeding, probably caused by cardiopulmonary resuscitation 2 days before start of treatment (autopsy findings), and one patient died of pulmonary embolism 45 minutes after therapy was started (no permission for autopsy).
In six other patients, treatment was prematurely stopped. In four patients (two patients in each group), therapy was discontinued because of severe bleeding. In two patients (both in the Fragmin group), therapy was discontinued because of withdrawal from the study by the attending physician for subsequent thrombectomy or thrombolytic therapy.
Bleeding Complications
Forty-eight patients treated with heparin and 37 treated with Fragmin had one or more hemorrhagic complications. In Table 3 , the most serious complication per patient is presented. In the heparin group, 13 patients had major and 35 patients had minor bleedings. In the Fragmin group, 10 patients had major and 27 had minor bleedings. These results correspond with a relative bleeding risk reduction of 21.2% for major and minor bleeding complications. The difference in the overall number of bleeding complications (major and minor combined) is Fall in hemoglobin level >1.5 mmol/l (no focus of bleeding) 3 3 Patients with major bleedings (n) 13 The total number of bleeding episodes was 118 in the heparin group and 103 in the Fragmin group. The difference is not significant. Most bleedings occurred on days 2 and 3 of treatment in both groups. The number of red cell transfusions given in both groups was not different: 28 units in the heparin group and 24 units in the Fragmin group. Also, the fall in hemoglobin level was similar in both groups.
For both drugs, bleedings occurred more often in the high-risk group than in the low-risk group. Overall, there were 29 minor and six major bleedings in the low-risk group and 33 minor and 17 major bleedings in the high-risk group, which is a significant difference (p=0.048).
Antithrombotic Efficacy
The results of the analysis of the efficacy of the treatment are summarized in Table 4 . A repeat perfusion scan was performed in 80 patients. The general condition of the other patients did not allow two scans. The basic characteristics, as listed for the whole study group in Tables 1 and 2 , did not differ in the two subgroups that had a repeat scan, except for a slightly higher age in the Fragmin group (mean age: heparin group, 49 years; Fragmin group, 58 years; p=0.04). The intensity of anticoagulation was not significantly different in the subgroups. In the heparin group, improvement was seen in 34 patients, no change was seen in six, and new high-probability defects were seen in six patients. In the Fragmin group, 26 patients had an improved repeat scan, five had scans that were unchanged, and three had scans that had new defects. These figures are not significantly different (95% confidence interval for the difference in new defects, -9.4% to +17.8%). None of the patients with new defects had clinical signs or symptoms of pulmonary embolism.
Repeat impedance plethysmography was performed in 93 of 115 patients with deep venous thrombosis. For various reasons, repeat impedance plethysmography was impossible in the other patients. Improvement was found in 22 of 43 patients in the heparin group and in 28 of 50 patients in the Fragmin group (95% confidence interval of the difference, -15.5% to +25.1%). The difference in the disappearance of pain and swelling was also not significant.
Adverse Effects
The liver function tests serum aspartate aminotransferase (ASAT, normal value <30 units/l) and serum alanine aminotransferase (ALAT, normal value <30 units/l) showed similar changes in median levels with a slight increase from 16.5 to 23.0 units/l for ASAT and 17.5 to 39.0 units/I for ALAT in the heparin group and from 17.0 to 24.5 units/l for ASAT and 22.5 to 45.0 units/l for ALAT in the Fragmin group. Thrombocytopenia (<100.000/gl) developed in two patients on heparin and in three on Fragmin. In three patients, this drop in platelet count coincided with sepsis with a positive blood culture. In the other two patients (one in each group), the thrombocytopenia may have been therapy related. No signs of allergy for the drugs were observed.
Discussion
The objective of this study was to determine whether or not, in patients with acute venous thromboembolism, the risk of bleeding associated with heparin treatment could be reduced with low molecular weight heparin (Fragmin) without loss of effectiveness. The results indicate that Fragmin and heparin have similar antithrombotic efficacy for equal ex vivo anti-Xa levels.
Monitoring of both treatments by ex vivo antifactor Xa activity levels resulted in a clinically fair balance between efficacy and bleeding risk. Although there is no strict relationship between anti-Xa levels, efficacy, and bleeding risk, the results of the study suggest that anti-Xa levels of about 0.5 unit/ ml Fragmin are optimal levels with respect to both the risk of bleeding and the risk of recurrent or progressive thromboembolism. For other low molecular weight heparins, separate studies are needed for the documentation of therapeutic regimens. For comparison between those, the international standard for low molecular weight heparin should be used. 19, 20 The number of minor bleeding complications in the heparin group was rather high compared with results from the literature. A conscientious daily follow-up and the inclusion of many high-risk patients may have influenced this outcome. The study population, however, gives a fair reflection of unselected patients in a university hospital because almost every eligible patient in the hospital was admitted to the trial. Purposely, we did not exclude critically ill patients with a high risk for bleeding because they would benefit most from a saver therapy. This design prompted us to assess the diagnosis of deep venous thrombosis with impedance plethysmography instead of venography and to accept that not all patients could be studied with lung scintigraphy.
We did not succeed, however, in establishing unequivocally that the low molecular weight heparin preparation produced less bleeding. A relative risk reduction for bleeding was found of 21.2% in favor of Fragmin, which was not significant. The trial was designed to detect, with sufficient power, a larger difference. The optimistic basic assumptions were based on animal studies, which suggested a large difference in the capacity to induce bleeding. The observed risk reduction for bleeding, however, may still offer a clinically important benefit, which should be proven in larger studies.
